Sacituzumab (powder)
Based on 8 publication(s) in Google Scholar
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 1796566-95-4
- Molecular Weight:145.52 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sacituzumab (powder)
More- Nat Commun. 2026 Apr 23;17(1):5600. [Abstract]
- J Immunother Cancer. 2026 May 7;14(5):e014671. [Abstract]
- J Chromatogr A. 2026 Jun 21:1777:466966. [Abstract]
- Bioconjug Chem. 2025 Aug 21. [Abstract]
- bioRxiv. 2026 May 27.
- Patent. US20260027227A1.
- Patent. US20250320310A1.
- KTH Royal Institute of Technology. 2025.
Biological Activity
Human IgG1 kappa
Human
Sacituzumab (0.5 nM, 800 s) possesses non-competitive binding sites and recognized distinct epitopes of TROP-2 on the antigen. Additionally, the binding to cancer cell lines activities of Sacituzumab and hIMB1636 is similar[1]. Sacituzumab (5 mg/mL, 48 h) binds to a linear epitope within TROP-2, which might not interrupt the assembly of TROP-2 molecules on the cell surface in HEK-293T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK-293T cells
-
Concentration:5 mg/mL
-
Incubation Time:48 h
-
Result:Bound to the linear epitopes of denatured TROP-2 proteins in HEK 293T cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB-468 xenograft model of 6-week-old female BALB/c nude mice[1]
-
Dosage:50 mg/kg
-
Administration:i.v., intervals of 5 days and repeated a total of four times
-
Result:Decreased the tumor inhibition rate to 29.1% at 50 mg/kg in MDA-MB-468 xenograft model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1796566-95-4
-
Appearance Lyophilized Powder
-
Molecular Weight 145.52 kDa
-
Color White to off-white
-
SMILES
[Sacituzumab (powder)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
High-throughput single-vesicle imaging platform for direct extracellular vesicle profiling of human plasma. [Abstract]2026 Apr 23;17(1):5600. PMID: 42020418 -
J Immunother Cancer
Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy. [Abstract]2026 May 7;14(5):e014671. PMID: 42097835 -
J Chromatogr A
Comprehensive evaluation of the analytical toolbox for commercial cysteine-linked antibody-drug conjugates. [Abstract]2026 Jun 21:1777:466966. PMID: 41962243 -
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
-
-
-
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zhou DD, et al. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2[J]. Int J Biol Macromol. 2023 Dec 31;253(Pt 6):127105. [Content Brief]
[2]. Sun M, et al. Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2[J]. iScience. 2021 Sep 30;24(10):103190. [Content Brief]
[3]. Shih LB, et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer[J]. Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s. [Content Brief]
[4]. Bardia A, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sacituzumab (powder) Related Classifications
HY-P99045A Related Classifications
Powered by Bioz